, GlobeNewswire
Addex Pharmaceuticals 2010 Financial Results Next Wednesday
Addex Pharmaceuticals /
Addex Pharmaceuticals 2010 Financial Results Next Wednesday
Verarbeitet und übermittelt durch Hugin.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Geneva, Switzerland, 18 February 2011 - Allosteric modulation company Addex
Pharmaceuticals (SIX:ADXN) will discuss its full-year 2010 financial results and
the status of key products in development during a teleconference and webcast
for investors, analysts and the media next Wednesday.
Title: Addex Full-Year 2010 Financial Results Conference
Call
Date: February 23, 2011
Time: 16:00 CET (15:00 GMT/10:00 EST)
To participate, please listen to the webcast or call one of the following
telephone numbers. RSVP is not necessary.
Dial-in numbers: +41 91 610 56 00 (Europe)
+44 203 059 58 62 (UK)
+1 866 291 4166 (USA)
The live webcast, slides, webcast replay and transcript, will be available at
www.addexpharma.com.
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops allosteric
modulators for human health. The company uses its proprietary discovery platform
to target cell surface receptors that are recognized as having therapeutic
potential for treating diseases of the central nervous system, metabolic
disorders or inflammation. Several Phase II clinical trials are expected to
start soon for two lead products: ADX48621 and ADX71149. ADX48621 is an mGluR5
negative allosteric modulator (NAM), which will be tested in Parkinson's disease
levodopa-induced dyskinesia (PD-LID) and, separately, non-Parkinsonian patients
suffering from dystonia, a movement disorder also observed in PD. The PD-LID
clinical trial is supported by a grant from the Michael J Fox Foundation.
ADX71149 is an mGluR2 positive allosteric modulator (PAM), which has potential
for treatment of schizophrenia, anxiety and other indications. ADX71149 is
licensed to Ortho-McNeil-Janssen Pharmaceuticals Inc., a subsidiary of Johnson &
Johnson. In addition, Merck & Co., Inc. has licensed rights to two preclinical
programs: mGluR4 PAM for Parkinson's disease and mGluR5 PAM for schizophrenia.
Unpartnered products in preclinical testing include: follicle stimulating
hormone receptor (FSHR) NAM, with potential for endometriosis and benign
prostatic hyperplasia; mGluR2 NAM for Alzheimer's disease; and GABA-B receptor
PAM with potential for chronic pain. Preclinical diabetes and inflammation
discovery programs include GLP1R PAM, IL1R1 NAM, and TNFR1 NAM.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that allosteric modulators of mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
Addex 2010 Results Invitation:
http://hugin.info/138017/R/1490606/426269.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1490606]
Addex Pharmaceuticals 2010 Financial Results Next Wednesday
Verarbeitet und übermittelt durch Hugin.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Geneva, Switzerland, 18 February 2011 - Allosteric modulation company Addex
Pharmaceuticals (SIX:ADXN) will discuss its full-year 2010 financial results and
the status of key products in development during a teleconference and webcast
for investors, analysts and the media next Wednesday.
Title: Addex Full-Year 2010 Financial Results Conference
Call
Date: February 23, 2011
Time: 16:00 CET (15:00 GMT/10:00 EST)
To participate, please listen to the webcast or call one of the following
telephone numbers. RSVP is not necessary.
Dial-in numbers: +41 91 610 56 00 (Europe)
+44 203 059 58 62 (UK)
+1 866 291 4166 (USA)
The live webcast, slides, webcast replay and transcript, will be available at
www.addexpharma.com.
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops allosteric
modulators for human health. The company uses its proprietary discovery platform
to target cell surface receptors that are recognized as having therapeutic
potential for treating diseases of the central nervous system, metabolic
disorders or inflammation. Several Phase II clinical trials are expected to
start soon for two lead products: ADX48621 and ADX71149. ADX48621 is an mGluR5
negative allosteric modulator (NAM), which will be tested in Parkinson's disease
levodopa-induced dyskinesia (PD-LID) and, separately, non-Parkinsonian patients
suffering from dystonia, a movement disorder also observed in PD. The PD-LID
clinical trial is supported by a grant from the Michael J Fox Foundation.
ADX71149 is an mGluR2 positive allosteric modulator (PAM), which has potential
for treatment of schizophrenia, anxiety and other indications. ADX71149 is
licensed to Ortho-McNeil-Janssen Pharmaceuticals Inc., a subsidiary of Johnson &
Johnson. In addition, Merck & Co., Inc. has licensed rights to two preclinical
programs: mGluR4 PAM for Parkinson's disease and mGluR5 PAM for schizophrenia.
Unpartnered products in preclinical testing include: follicle stimulating
hormone receptor (FSHR) NAM, with potential for endometriosis and benign
prostatic hyperplasia; mGluR2 NAM for Alzheimer's disease; and GABA-B receptor
PAM with potential for chronic pain. Preclinical diabetes and inflammation
discovery programs include GLP1R PAM, IL1R1 NAM, and TNFR1 NAM.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that allosteric modulators of mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
Addex 2010 Results Invitation:
http://hugin.info/138017/R/1490606/426269.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1490606]
Relevante Links: Addex Therapeutics Ltd